MaxCyte (MXCT) closed at $1.25 on Oct 14, 2026, up 29.7% on the day. The stock is up 5.0% over the past month, down 7.4% over three months, down 19.4% year to date and down 21.9% over the past year. It trades 30.7% below its 52-week high of $1.80 and 94.4% above its 52-week low of $0.64. The close sits above its 50-day moving average ($1.21) and above its 200-day moving average ($1.06).
Yes — the Oct 14, 2026 close of $1.25 is 17.6% above the 200-day average of $1.06.
MXCT closed 30.7% below its 52-week high of $1.80.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
